Focused on immunology-based therapies for infectious diseases, this biotech company reported a notable insider sale in recent ...

Odyssey Therapeutics secured a valuation of $899.9 million after its shares rose 11.1% in their Nasdaq debut on Friday, signaling ​solid investor demand for biotech offerings. The shares of ‌the ...

Following a turbulent year for the markets in general and biotech in particular, the industry made a notable recovery, ...

Discover the role of biotechnology in healthcare, medicine, and investment. Understand biotech processes, top companies, and ...

(Michael on for Roanna Ruiz), Leerink Partners: "what would constitute a clear signal as a green light to initiate Phase III in 2027?"; President, CEO & Director De Backer: "it's going to really be ...

In 2026, the biotech landscape has undergone a seismic shift, moving beyond the hype cycles of the past decade into a phase of tangible, life-saving applications. With the first wave of CRISPR-based ...

Virginia has invested in recent years to become a leader in biotechnology. This week, city and state leaders cut the ribbon ...

Latus Bio raised $42 million as it prepares to seek FDA approval to start a clinical trial for its gene therapy for ...

For years, the narrative around AI in drug discovery was one of potential—faster target identification, cheaper molecule optimization, and the promise of curing the incurable. But in 2026, that ...

Krystal Biotech delivered strong Q1 2026 results, with Vyjuvek sales up 32% YoY to $116.4M and gross margin expanding to 95%.